Neuronetics Inc stock (US63009R1005): Nasdaq shares steady as investors look beyond Q1 update

Neuronetics shares on Nasdaq traded broadly sideways on Friday as the United States-based neuromodulation specialist remained in focus following its early-May 2026 first-quarter report and continued rollout of its NeuroStar depression therapy system.

Neuronetics Inc shares traded largely unchanged on the Nasdaq on Friday, with the United States-based medical technology company still being assessed by investors after its early-May 2026 first-quarter update on the NeuroStar transcranial magnetic stimulation platform for major depressive disorder, according to Nasdaq price data as of 05/29/2026.

The stock, listed in New York under the ticker STIM and denominated in USD, has been oscillating in a narrow band since the company released its Q1 2026 figures in early May, when management reiterated its focus on expanding NeuroStar system placements at US psychiatric and behavioral health practices, according to the companys investor relations materials published in May 2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Neuronetics Inc
• Sector/industry: Medical technology - neuromodulation for mental health
• Headquarters/country: Malvern, United States
• Core markets: Outpatient psychiatric and behavioral health clinics, primarily in the United States
• Key revenue drivers: NeuroStar TMS system sales, treatment session utilization, service and support contracts
• Home exchange/listing venue: Nasdaq (STIM)
• Trading currency: USD

Neuronetics Inc: core business model

Focusing on mental health providers, Neuronetics Inc commercializes its NeuroStar transcranial magnetic stimulation devices and related treatment consumables to drive recurring revenue from depression therapy sessions at clinics.

Valuation metrics and multiples for Neuronetics Inc

With trading centered on the Nasdaq in the United States, Neuronetics is viewed as an early-stage medical technology name where traditional valuation indicators such as price-to-earnings are of limited use because the business has reported net losses in recent periods, according to the companys latest annual and quarterly filings released in 2025 and early May 2026.

Investors instead tend to monitor revenue growth, gross margin trends on NeuroStar systems and treatment sessions, and the companys path toward adjusted profitability, metrics that were highlighted in Neuronetics Q1 2026 update in early May 2026 and that continue to influence how the market prices the shares relative to other US-listed mental health device developers.

Conclusion

Neuronetics shares on Nasdaq were broadly flat on Friday as the market continued to digest the companys early-May 2026 first-quarter report and the latest data on NeuroStar system adoption in the United States.

Given the lack of net earnings so far, investors appear to focus more on revenue expansion, utilization trends and cash burn than on conventional valuation multiples when they assess the stock alongside other US-listed mental health device specialists.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.